Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
  • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
  • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
  • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
  • C07D213/72—Nitrogen atoms
  • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/06—Antimigraine agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents
  • A61P35/04—Antineoplastic agents specific for metastasis
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
  • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
  • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
  • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
  • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
  • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
  • C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
  • C07D211/16—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with acylated ring nitrogen atom
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
  • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
  • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
  • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
  • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
  • C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
  • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
  • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
  • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
  • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
  • C07D211/30—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom
  • C07D211/32—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom by oxygen atoms
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
  • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
  • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
  • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
  • C07D211/40—Oxygen atoms
  • C07D211/44—Oxygen atoms attached in position 4
  • C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
  • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
  • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
  • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
  • C07D211/40—Oxygen atoms
  • C07D211/44—Oxygen atoms attached in position 4
  • C07D211/52—Oxygen atoms attached in position 4 having an aryl radical as the second substituent in position 4
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
  • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
  • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
  • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
  • C07D211/56—Nitrogen atoms
  • C07D211/58—Nitrogen atoms attached in position 4
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
  • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
  • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
  • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
  • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
  • C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
  • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
  • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
  • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
  • C07D239/32—One oxygen, sulfur or nitrogen atom
  • C07D239/42—One nitrogen atom
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
  • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
  • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
  • C07D295/182—Radicals derived from carboxylic acids
  • C07D295/192—Radicals derived from carboxylic acids from aromatic carboxylic acids
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
  • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
  • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
  • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
  • C07D333/24—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
  • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
  • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
  • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
  • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
  • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
  • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
  • C07D487/08—Bridged systems

Definitions

• the invention relates to compounds of the formula I.
• R 4 , R 4 are each independently absent, A, OH or OA, ⁇ ⁇ -
• a unbranched or branched alkyl having 1-10 C atoms, wherein one or two CH 2 groups by O or S atoms and / or by -CH CH groups and / or 1-7 H atoms by F can be replaced, Ar unsubstituted or one, two or three times by shark, A,
• Phenyl, Het is a mono- or dinuclear saturated, unsaturated or aromatic heterocycle with 1 to 4 N-, O- and / or S-
• the invention also relates to the optically active forms, the racemates, the diastereomers and the hydrates and solvates, e.g. Alcoholates, these compounds.
• the object of the invention was to find new compounds with valuable properties, in particular those which can be used for the production of medicaments. It has been found that the compounds of the formula I and their salts have very valuable pharmacological properties with good tolerability. In particular, they show factor Xa inhibitory properties and can therefore be used to combat and prevent thromboembolic disorders such as thrombosis, myocardial infarction, arteriosclerosis, inflammation, apoplexy, angina pectoris, restenosis after angioplasty and intermittent claudication.
• thromboembolic disorders such as thrombosis, myocardial infarction, arteriosclerosis, inflammation, apoplexy, angina pectoris, restenosis after angioplasty and intermittent claudication.
• the compounds of the formula I according to the invention are furthermore inhibitors of the coagulation factors factor VIIa, factor IXa and thrombin of the blood coagulation cascade.
• Aromatic amides are described in WO 99/00121 and in WO 00/39118.
• Aromatic amidine derivatives with antithrombotic activity are e.g. known from EP 0 540 051 B1.
• Cyclic guanidines for the treatment of thromboembolic disorders are e.g. described in WO 97/08165.
• Aromatic heterocycles with factor Xa inhibitory activity are e.g. known from WO 96/10022.
• Substituted N - [(aminoimino-methyl) phenylalkyl] azaheterocyclylamides as factor Xa inhibitors are described in WO 96/40679.
• the antithrombotic and anticoagulant effect of the compounds according to the invention is attributed to the inhibitory activity against the activated coagulation protease, known under the name factor Xa, or to the inhibition of other activated serine proteases such as factor VIIa, factor IXa or thrombin.
• Factor Xa is one of the proteases involved in the complex process of blood clotting. Factor Xa catalyzes the conversion of prothrombin to thrombin. Thrombin cleaves fibrinogen into fibrin monomers that after cross-linking make an elementary contribution to thrombus formation. Activation of thrombin can lead to the occurrence of thromboembolic disorders. An inhibition of thrombin can, however, in the
• the measurement of the inhibition of thrombin can e.g. using the method of G.F. Cousins et al. in Circulation 1996, 94, 1705-1712.
• Inhibition of factor Xa can thus prevent thrombin from being formed.
• the compounds of formula I according to the invention and their salts interfere with the blood coagulation process by inhibiting factor Xa and thus inhibit the formation of thrombi.
• the inhibition of factor Xa by the compounds according to the invention and the measurement of the anticoagulant and antithrombotic activity can be determined by customary in vitro or in vivo methods.
• a suitable method is e.g. by J. Hauptmann et al. in Thrombosis and Haemostasis 1990, 63, 220-223.
• the measurement of the inhibition of factor Xa can e.g. using the method of T. Hara et al. in thromb. Haemostas. 1994, 71, 314-319.
• the coagulation factor VIa initiates the extrinsic part of the coagulation cascade after binding to the tissue factor and contributes to the activation of factor X to factor Xa. Inhibition of factor VIIa thus prevents the development of factor Xa and thus the subsequent formation of thrombin.
• the inhibition of the factor VIIa by the compounds according to the invention and the measurement of the anticoagulant and antithrombotic activity can be determined by customary in vitro or in vivo methods.
• a common method for measuring the inhibition of factor VIIa is described, for example, by HF Ronning et al. in Thrombosis Research 1996, 84, 73-81.
• Coagulation factor IXa is generated in the intrinsic coagulation cascade and is also involved in the activation of factor X to factor Xa. Inhibition of factor IXa can therefore otherwise prevent factor Xa from being formed.
• the inhibition of factor IXa by the compounds according to the invention and the measurement of the anticoagulant and antithrombotic activity can be determined by customary in vitro or in vivo methods. A suitable method is e.g. by J. Chang et al. in Journal of Biological Chemistry 1998, 273, 12089-12094.
• the compounds according to the invention can furthermore be used for the treatment of tumors, tumor diseases and / or tumor metastases.
• the compounds of formula I can be used as active pharmaceutical ingredients in the
• thromboembolic disorders such as Thrombosis, myocardial infarction, arteriosclerosis, inflammation, apoplexy, angina pectoris, restenosis after angioplasty, claudication intermittently, venous thrombosis, pulmonary embolism, arterial thrombosis, myocardial ischemia, unstable angina and thrombosis-based
• the compounds of the invention are also used for treatment or
• the compounds are also used in combination with other thrombolytics for myocardial infarction, as well as for prophylaxis for reocclusion after thrombolysis, percutaneous transluminal angioplasty (PTCA) and coronary bypass surgery.
• thrombolytics for myocardial infarction
• prophylaxis for reocclusion after thrombolysis
• percutaneous transluminal angioplasty PTCA
• coronary bypass surgery percutaneous transluminal angioplasty
• the compounds according to the invention are also used for the prevention of rethrombosis in microsurgery, also as anticoagulants in connection with artificial organs or in hemodialysis.
• the compounds are also used in the cleaning of catheters and medical devices in patients in vivo, or as anticoagulants for the preservation of blood, plasma and other blood products in vitro.
• the compounds according to the invention are also used in diseases in which blood coagulation makes a decisive contribution to the course of the disease or is a source of secondary pathology, such as e.g. cancer including metastasis, inflammatory diseases including arthritis and diabetes.
• the compounds according to the invention are also used to treat migraines (F. Morales-Asin et al., Headache, 40, 2000, 45-47).
• the compounds according to the invention are also used in combination with other thrombolytically active compounds, for example with the "tissue plasminogen activator "t-PA, modified t-PA, streptokinase or urokinase.
• t-PA tissue plasminogen activator
• modified t-PA modified t-PA
• streptokinase or urokinase.
• the compounds according to the invention are administered with the other substances mentioned either simultaneously or before or after.
• Simultaneous administration with aspirin is particularly preferred in order to prevent recurrence of thrombus formation.
• the compounds according to the invention are also used in combination with platelet glycoprotein receptor (IIb / IIla) antagonists which inhibit platelet aggregation.
• IIb / IIla platelet glycoprotein receptor
• the invention relates to the compounds of the formula I and their salts and to a process for the preparation of compounds of the formula I according to claim 1 and their salts, characterized in that
• R 1 , R 4 , R 4 , E, Q, T, Z and Z ' have the meanings given in Claim 1,
• L denotes Cl, Br, I or a free or reactively functionally modified OH group and R 1 and D have the meanings given in claim 1, implements,
• the invention also relates to the optically active forms (stereoisomers), the enantiomers, the racemates, the diastereomers and the hydrates and solvates of these compounds.
• Solvates of the compounds are understood to mean the addition of inert solvent molecules to the compounds, which are formed on account of their mutual attraction. Solvates are e.g. Mono- or dihydrates or alcoholates.
• compositions are e.g. the salts of the compounds according to the invention and also so-called prodrug compounds.
• Prodrug derivatives are understood with z. B. alkyl or acyl groups, sugars or oligopeptides modified compounds of formula I, which are quickly cleaved in the organism to the active compounds of the invention. This also includes biodegradable polymer derivatives of the compounds according to the invention. B. in Int. J. Pharm. 115. 61-67 (1995).
• the invention also relates to mixtures of the compounds of the formula I according to the invention, e.g. Mixtures of two diastereomers e.g. in the ratio 1: 1, 1: 2, 1: 3, 1: 4, 1: 5, 1:10, 1: 100 or 1: 1000. These are particularly preferably mixtures of stereoisomeric compounds.
• A is preferably methyl, furthermore ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl or tert-butyl, furthermore also pentyl, 1-, 2- or 3-methylbutyl, 1, 1-, 1, 2- or 2,2-dimethylpropyl, 1-ethylpropyl, hexyl, 1-, 2-, 3- or 4-methylpentyl, 1, 1-, 1, 2-, 1, 3-, 2,2-, 2,3- or 3,3-dimethylbutyl, 1- or 2-ethylbutyl, 1-ethyl-1-methylpropyl, 1-ethyl-2-methylpropyl, 1, 1, 2- or 1, 2,2-trimethylpropyl, more preferably e.g. Trifluoromethyl.
• Cycloalkyl has 3-7 C atoms and preferably means cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl or cycloheptyl.
• Ar means, for example, phenyl, o-, m- or p-tolyl, o-, m- or p-ethylphenyl, o-, m- or p-propylphenyl, o-, m- or p-isopropylphenyl, o-, m- or p-tert-butylphenyl, o-, m- or p-hydroxyphenyl, o-, m- or p-nitrophenyl, o-, m- or p-aminophenyl, o-, m- or p- (N-methylamino ) -phenyl, o-, m- or p- (N-methylaminocarbonyl) -phenyl, o-, m- or p-acetamidophenyl, o-, m- or p-methoxyphenyl, o-, m- or
• Ar preferably means, for example, phenyl which is unsubstituted or mono-, di- or trisubstituted by shark, A, OR 2 , NR 2 COA, SO 2 A, COOR 2 or CN.
• Ar particularly preferably denotes, for example, phenyl which is unsubstituted or mono-, di- or trisubstituted by shark, A, OR 3 or NHCOA, such as 0, for example phenyl, o-, m- or p-methylphenyl, o-, m- or p-hydroxyphenyl, o-, m- or p-methoxyphenyl, 2-, 3- or 4-chlorophenyl, 4-bromophenyl, 3-fluoro-4-trifluoromethoxyphenyl, 4-ethoxyphenyl, 3-cyanophenyl, o-, m- or p-acetamidophenyl or 4-ethoxycarbonyl-phenyl.
• Ar very particularly preferably denotes unsubstituted phenyl, 4-chlorophenyl, 4-fluorophenyl, 2,3-difluorophenyl, 2-chlorophenyl, 4-hydroxyphenyl, 2- or 4-methoxyphenyl or 4-acetamidophenyl.
• Q Ar ' preferably has the preferred meanings given for Ar.
• Het means e.g. 2- or 3-furyl, 2- or 3-thienyl, 1-, 2- or 3-pyrrolyl, 1-, 2, 4- or 5-imidazolyl, 1-, 3-, 4- or 5-pyrazolyl, 2 -, 4- or 5-
• 6- or 7-benzisothiazolyl 4-, 5-, 6- or 7-benz-2,1, 3-oxadiazolyl, 2-, 3-,
• Het can, for. B. also mean 2,3-dihydro-2-, -3-, -4- or -5-furyl, 2,5-dihydro-2-, -3-, -4- or 5-furyl, tetrahydro-2 - or -3-furyl, 1, 3-dioxolan-4-yl, tetrahydro-2- or -3-thienyl, 2,3-dihydro-1-, -2-, -3-, -4- or -5-pyrrolyl, 2,5-dihydro-1-, -2-, -3-, -4- or -5-pyrrolyl, 1-, 2- or 3-pyrrolidinyl, tetrahydro-1-, -2 - or -4-imidazolyl, 2,3-dihydro-1-, -2-, -3-, -4- or -5-pyrazolyl, tetrahydro-1-, -3- or -4-pyrazolyl, 1, 4
• Atoms that can be unsubstituted or substituted one or two times by carbonyl oxygen, OH or OA are atoms that can be unsubstituted or substituted one or two times by carbonyl oxygen, OH or OA.
• Het preferably means e.g. Furyl, thienyl, thiazolyl, imidazolyl, [2,1, 3] -
• Tetrahydropyranyl piperazinyl, pyrazinyl, piperidinyl or pyrrolidinyl, optionally substituted by carbonyl oxygen, such as e.g. 3-oxomorpholin-4-yl, 2-oxopiperidin-1-yl or 2-oxopyrrolidin-1-yl.
• Het very particularly preferably means thienyl, imidazolyl, pyridyl, indolyl, piperidinyl, piperazinyl, 2-oxopiperazinyl, morpholinyl, tetrahydropyran-4-yl, 3-oxomorpholin-4-yl, 2-oxo-2 / - / -pyrazin-1-yl, 2-oxopyrrolidin-1-yl or 2-oxopiperidin-1-yl.
• Het ' preferably has the preferred meanings given for Ar.
• D especially means e.g. phenyl which is unsubstituted or mono- or disubstituted by shark, A, hydroxyl, methoxy, ethoxy, hydroxycarbonyl, methoxycarbonyl or ethoxycarbonyl, or unsubstituted or monosubstituted by shark, pyridyl or thienyl.
• D very particularly preferably denotes 4-chlorophenyl.
• R 1 is preferably Ar, such as phenyl, o-, m- or p-fluorophenyl, o-, m- or p-chlorophenyl, o-, m- or p-hydroxyphenyl, o-, m- or p-methoxyphenyl or difluorophenyl; Het, such as thienyl or furyl;
• Cycloalkyl such as cyclohexyl; or A, which can be substituted once by OR 2 , such as methyl, ethyl, propyl, butyl, -CH (CH 3 ) OH or -CH (CH 3 ) OCH 3)
• R 1 particularly preferably denotes phenyl which is unsubstituted or mono-, di- or trisubstituted by shark, OH or OA, such as phenyl, o-, m- or p-fluorophenyl, o-, m- or p-chlorophenyl, o-, m- or p-hydroxyphenyl, o-, m- or p-methoxyphenyl, difluorophenyl or trifluorophenyl; a mononuclear aromatic heterocycle with 1 to 2 N, O and / or S atoms, such as thienyl or furyl; or A, which can be substituted once by OR 3 , such as methyl, ethyl, propyl, butyl,
• R 2 is preferably, for example, H or alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms, very particularly preferably H.
• the unsubstituted saturated carbocycle preferably means cyclopentyl or cyclohexyl.
• T means in particular piperidin-yl, piperazinyl, pyridinyl, 2-oxopiperidin-1-yl, 2-oxopiperidin-4-yl, 2-oxopyrrolidin-1-yl, pyrrolidin-1-yl, 2-
• Oxo-1H-pyridin-1-yl, 3-oxomorpholin-4-yl, morpholin-4-yl, 4-oxo-1H-pyridin-1-yl, 2,6-dioxopiperidin1-yl, 2- Oxo-piperazin-1-yl, 2,6-dioxopiperazin-1-yl, 2,5-dioxo-pyrrolidin-1-yl, 2-oxo-1, 3-oxazolidin-3-yl, pyridazinyl, 3-oxo-2-pyridazin-2-yl, 2-caprolactam-1-yl ( 2-oxo-azepan-1-yl),
• 6-oxopiperazin-1-yl 6-azabicyclo [2.2.2] octan-3-one-2-yl, 5,6-dihydro-1 H-pyrimidin-2-oxo-1-yl, 2-oxo- [1, 3] oxazinan-3-yl or 4 7- [1, 4] oxazin-4-yl, where the radicals can additionally be substituted simply by A, unsubstituted or one, two or three times by
• R 4 , R 4 ' are absent, Z, Z' are each ethylene
• the compounds of formula I can have one or more chiral centers and therefore exist in various stereoisomeric forms.
• Formula I encompasses all of these forms. Accordingly, the invention relates in particular to those compounds of the formula I in which at least one of the radicals mentioned has one of the preferred meanings indicated above.
• Some preferred groups of compounds can be expressed by the following sub-formulas Ia to Ib, which correspond to the formula I and in which the radicals not specified have the meaning given for the formula I, but in which
• A which can be substituted by OR 2 , means; in li R 1 unsubstituted or single, double or triple by shark,
• R J mean H; in Im Z, Z 'mean ethylene;
• Carbocycle mean; in lo A denotes unbranched or branched alkyl having 1-10 C atoms, in which 1-7 H atoms can be replaced by F;
• R 1 Ar, Het, cycloalkyl or
• Q is missing, 0 or CH 2 .
• R 4 , R 4> are each independently absent, A, OH or OA,
• R 4 and R 4 together also methylene or ethylene
• R 4 , R 4 are each independently absent, A, OH or OA, R 4 and R 4 together also methylene or ethylene,
• Carbocycle A unbranched or branched alkyl having 1 -10 C atoms, in which 1-7 H atoms can be replaced by F, shark F, Cl, Br or I;
• R 1 is thienyl, furyl, unsubstituted or mono-, di- or trisubstituted by Hal, OH or OA-substituted phenyl, o the
• Q is missing, O or CH 2 .
• R 3 H or A, R 4 , R 4 ' are each independently absent, A, OH or OA,
• R 4 and R 4 together also methylene or ethylene
• R 1 thienyl, furyl, unsubstituted or mono-, di- or trisubstituted by shark, OH or OA-substituted phenyl, 0 or A, which may be substituted by OR 3 ,
• Q is absent, O or CH 2 , 0 R 2 H or A,
• A denotes unbranched or branched alkyl having 1-10 C atoms, in which 1-7 H atoms can be replaced by F, Hai F, Cl, Br or I; as well as their pharmaceutically usable derivatives, solvates and stereoisomers, including their mixtures in all ratios.
• the starting materials can also be formed in situ, so that they are not isolated from the reaction mixture, but instead are immediately reacted further to give the compounds of the formula I.
• Y is O, can preferably be obtained by reacting compounds of the formula II with compounds of the formula III.
• the reaction is usually carried out in an inert solvent, if appropriate in the presence of an organic base such as triethylamine, dimethylaniline, pyridine or quinoline.
• an organic base such as triethylamine, dimethylaniline, pyridine or quinoline.
• the reaction time is between a few minutes and 14 days, preferably between one and ten hours, the reaction temperature between approximately 0 ° and 150 °, normally between 10 ° and 130 °, preferably between 10 ° and 90 °, very particularly preferably between 20 c and 80 ° C.
• Suitable inert solvents are e.g. Water; Hydrocarbons such as hexane, petroleum ether, benzene, toluene or xylene; chlorinated hydrocarbons such as trichlorethylene, 1, 2-dichloroethane, carbon tetrachloride, chloroform or dichloromethane; Alcohols such as methanol, ethanol, isopropanol, n-
• Ethers such as diethyl ether, diisopropyl ether
• the starting compounds of the formulas II and III are generally known. If they are new, they can be manufactured according to methods known per se.
• L is preferably Cl, Br, I or a reactively modified OH group such as e.g. an activated ester, an imidazolide or alkylsulfonyloxy with 1-6 C atoms (preferably methylsulfonyloxy or trifluoromethylsulfonyloxy) or arylsulfonyloxy with 6-
• a reactively modified OH group such as e.g. an activated ester, an imidazolide or alkylsulfonyloxy with 1-6 C atoms (preferably methylsulfonyloxy or trifluoromethylsulfonyloxy) or arylsulfonyloxy with 6-
• Activated esters are conveniently formed in situ, e.g. B. by adding HOBt or N-hydroxysuccinimide.
• the reaction is usually carried out in an inert solvent, in the presence of an acid-binding agent, preferably an alkali or alkaline earth metal hydroxide, carbonate or bicarbonate or another salt of a weak acid of the alkali or alkaline earth metals, preferably potassium, Sodium, calcium or cesium.
• an acid-binding agent preferably an alkali or alkaline earth metal hydroxide, carbonate or bicarbonate or another salt of a weak acid of the alkali or alkaline earth metals, preferably potassium, Sodium, calcium or cesium.
• the supply ⁇ 5 set an organic base such as triethylamine, dimethylaniline, pyridine or quinoline, or an excess of the amine component of formula IV may be favorable.
• the reaction time is between a few minutes and 14 days, the reaction temperature is between about 0 ° and 150 °, normally between 20 ° and 0 130 °. Suitable inert solvents are those mentioned above.
• compositions according to the invention mentioned can be used in their final non-salt form.
• present invention also encompasses the use of these compounds in the form of their pharmaceutically acceptable salts which can be derived from various organic Q and inorganic acids and bases by methods which are known in the art.
• Most of the pharmaceutically acceptable salt forms of the compounds of formula I are prepared conventionally. If the compound of formula I contains a carboxylic acid group, one of its suitable salts can be formed by reacting the compound with a suitable base to give the corresponding base addition salt.
• Such bases are, for example, alkali metal hydroxides, including potassium hydroxide, sodium hydroxide and lithium hydroxide; Alkaline earth metal hydroxides such as barium hydroxide and calcium hydroxide; Alkali metal alcoholates, for example potassium ethanolate and sodium propanolate; as well as various organic bases such as piperidine, diethanolamine and N-methylglutamine.
• alkali metal hydroxides including potassium hydroxide, sodium hydroxide and lithium hydroxide
• Alkaline earth metal hydroxides such as barium hydroxide and calcium hydroxide
• Alkali metal alcoholates for example potassium ethanolate and sodium propanolate
• various organic bases such as piperidine, diethanolamine and N-methylglutamine.
• the aluminum salts of the compounds of formula I also count.
• acid addition salts can be formed by reacting these compounds with pharmaceutically acceptable organic and inorganic acids, for example hydrogen halides such as hydrogen chloride, hydrogen bromide or hydrogen iodide, other mineral acids and their corresponding salts such as sulfate, nitrate or phosphate and the like and also Treated alkyl and monoarylsulfonates such as ethanesulfonate, toluenesulfonate and benzenesulfonate, as well as other organic acids and their corresponding salts such as acetate, tri-fluoroacetate, tartrate, maleate, succinate, citrate, benzoate, salicylate, ascorbate and the like.
• organic and inorganic acids for example hydrogen halides such as hydrogen chloride, hydrogen bromide or hydrogen iodide, other mineral acids and their corresponding salts such as sulfate, nitrate or phosphate and the like and also Treated alkyl and monoarylsulfonates
• pharmaceutically acceptable acid addition salts of the compounds of the formula I include the following: acetate, adipate, alginate, arginate, aspartate, benzoate, benzenesulfonate (besylate), bisulfate, bisulfite, bromide, butyrate, camphorate, combat sulfonate, caprylate, chloride, chlorobenzene , Citrate, cyclopentane propionate, di-gluconate, dihydrogen phosphate, dinitrobenzoate, dodecyl sulfate, ethane sulfonate, fumarate, galacterate (from mucic acid), galacturonate, glucohepanoate, gluconate, glutamate, glycerophosphate, hemisuccinate, hemisuccinate
• the base salts of the compounds according to the invention further include aluminum, ammonium, calcium, copper, iron (III), iron (II), lithium thium, magnesium, manganese (III), manganese (II), potassium, sodium and zinc salts, but this should not be a limitation.
• Preferred among the salts mentioned above are ammonium; the alkali metal salts sodium and potassium, and the alkaline earth metal salts calcium and magnesium.
• Salts of the compounds of formula I which are derived from pharmaceutically acceptable organic non-toxic bases include salts of primary, secondary and tertiary amines, substituted amines, including naturally occurring substituted amines, cyclic amines and basic ion exchange resins, e.g.
• Arginine betaine, caffeine, chlorprocaine, choline, N, N'-dibenzylethylenediamine (benzathine), dicyclohexylamine, diethanolamine, diethylamine, 2-diethylaminoethanol, 2-dimethylaminoethanol, ethanolamine, ethylenediamine, N-ethylmorpholine, N-ethylpiperidine Glucosamine, histidine, hydrabamine, iso-propylamine, lidocaine, lysine, meglumine, N-methyl-D-glucamine, morpholine, piperazine, piperidine, polyamine resins, procain, purines, theobromine, triethanolamine, triethylamine, trimethylamine, tripropylamine and tris (hydroxymethyl ) methylamine
• Compounds of the present invention which contain basic nitrogen-containing groups can be prepared using agents such as (C 1 -C 4 ) alkyl halides, for example methyl, ethyl, isopropyl and tert-butyl chloride, bromide and iodide; Di (-C 4 ) alkyl sulfates, such as dimethyl, diethyl and diamyl sulfate; (C 10 - Ci 8 ) alkyl halides, for example decyl, dodecyl, lauryl, myristyl and stearyl chloride, bromide and iodide; and quaternize aryl (C 1 -C 4 ) alkyl halides, for example benzyl chloride and phenethyl bromide.
• Such salts can be used to prepare both water-soluble and oil-soluble compounds according to the invention.
• the above-mentioned pharmaceutical salts which are preferred include acetate, trifluoroacetate, besylate, citrate, fumarate, gluconate, hemisuccinate, hippurate, hydrochloride, hydrobromide, isethionate, mandelate, meglumine, nitrate, oleate, phosphonate, pivalate, sodium phosphate, Stearate, sulfate, Sulfosalicylate, tartrate, thiomalate, tosylate and tromethamine, but this is not intended to be a limitation.
• the free base can be regenerated in a conventional manner by bringing the salt form into contact with a base and isolating the free base.
• the free base forms differ in a sense from their corresponding salt forms in terms of certain physical properties such as solubility in polar solvents; in the context of the invention, however, the salts otherwise correspond to their respective free base forms.
• the pharmaceutically acceptable base addition salts of the compounds of the formula I are formed with metals or amines such as alkali metals and alkaline earth metals or organic amines.
• metals are sodium, potassium, magnesium and calcium.
• Preferred organic amines are N.N'-dibenzylethylenediamine, chloroprocaine, choline, diethanolamine, ethylenediamine, N-methyl-D-glucamine and procaine.
• the base addition salts of acidic compounds according to the invention are prepared by contacting the free acid form with a sufficient amount of the desired base, whereby the salt is prepared in the usual way.
• the free acid can be regenerated in a conventional manner by contacting the salt form with an acid and isolating the free acid.
• the free acid forms differ in a sense from their corresponding salt forms in terms of certain physical properties such as solubility in polar solvents; in the context of the invention, however, the salts otherwise correspond to their respective free acid forms.
• the invention also includes multiple salts. Typical multiple salt forms include, for example, bitartrate, diacetate, difumarate, dimeglumine, diphosphate,
• the term "pharmaceutically acceptable salt” in the present context is to be understood as meaning an active ingredient which contains a compound of the formula I in the form of one of its salts, in particular when this salt form contains the active ingredient Gives improved pharmacokinetic properties compared to the free form of the active ingredient or any other salt form of the active ingredient that was used previously.
• the pharmaceutically acceptable salt form of the active ingredient can also give this active ingredient a desired pharmacokinetic property which it did not previously have, and can even have a positive influence on the pharmacodynamics of this active ingredient with regard to its therapeutic effectiveness in the body.
• the pharmaceutical activity of the racemates or the stereoisomers of the compounds according to the invention can differ, it may be desirable to use the enantiomers.
• the end product or even the intermediates can be separated into enantiomeric compounds by chemical or physical measures known to the person skilled in the art, or can already be used as such in the synthesis.
• diastereomers are formed from the mixture by reaction with an optically active release agent. Suitable release agents are, for example, optically active acids, such as the R and S forms of
• Tartaric acid diacetyltartaric acid, dibenzoyltartaric acid, mandelic acid, malic acid, lactic acid, suitable N-protected amino acids (e.g. N-benzoylproline or N-benzenesulfonylproline) or the various optically active camphorsulfonic acids.
• suitable N-protected amino acids e.g. N-benzoylproline or N-benzenesulfonylproline
• optically active camphorsulfonic acids e.g. N-benzoylproline or N-benzenesulfonylproline
• Chromatographic separation of enantiomers using an optically active separating agent e.g. dinitrobenzoylphenylglycine, cellulose triacetate or other derivatives of
• Carbohydrates or chiral derivatized methacrylate polymers fixed on silica gel Carbohydrates or chiral derivatized methacrylate polymers fixed on silica gel).
• Aqueous or alcoholic solvent mixtures such as e.g. Hexane / isopropanol / acetonitrile e.g. in the ratio 82: 15: 3.
• the invention further relates to the use of the compounds of the formula I and / or their physiologically acceptable salts for the production of pharmaceutical preparations, in particular in a non-chemical way. They can be brought into a suitable dosage form together with at least one solid, liquid and / or semi-liquid carrier or auxiliary and, if appropriate, in combination with one or more further active ingredients.
• the invention further relates to medicaments containing at least one compound of the formula I and / or its pharmaceutically usable derivatives, solvates and stereoisomers, including their mixtures in all ratios, and, if appropriate, carriers and / or auxiliaries.
• compositions can be presented in the form of dose units containing a predetermined amount of active ingredient per dose unit.
• a unit can contain, for example, 0.5 mg to 1 g, preferably 1 mg to 700 mg, particularly preferably 5 mg to 100 mg, of a compound according to the invention, depending on the compound treated Disease condition, route of administration and age, weight and
• Condition of the patient, or pharmaceutical formulations can be in
• dosage unit formulations are those which contain a daily dose or partial dose, as stated above, or a corresponding fraction thereof of an active ingredient. Furthermore, such pharmaceutical formulations can be produced using one of the methods generally known in the pharmaceutical field.
• compositions can be administered for administration by any suitable route, for example by oral (including buccal or sublingual), rectal, nasal, topical (including buccal, sublingual or transdermal), vaginal or parenteral (including subcutaneous, intramuscular, intravenous or intradermal) ways to adapt.
• oral including buccal or sublingual
• rectal nasal
• topical including buccal, sublingual or transdermal
• vaginal or parenteral including subcutaneous, intramuscular, intravenous or intradermal
• parenteral including subcutaneous, intramuscular, intravenous or intradermal
• compositions adapted for oral administration can be used as separate units, e.g. Capsules or tablets; Powder or granules; Solutions or suspensions in aqueous or non-aqueous liquids; edible foams or foam dishes; or oil-in-water liquid emulsions or water-in-oil liquid emulsions.
• the active ingredient component in the case of oral administration in the form of a tablet or capsule, can be combined with an oral, non-toxic and pharmaceutically acceptable inert carrier, such as ethanol, glycerol, water and others. Powders are made by crushing the compound to an appropriate fine size and mixed with a similarly crushed pharmaceutical carrier such as an edible carbohydrate such as starch or mannitol. A flavor, preservative, dispersant and color may also be present.
• an oral, non-toxic and pharmaceutically acceptable inert carrier such as ethanol, glycerol, water and others.
• Powders are made by crushing the compound to an appropriate fine size and mixed with a similarly crushed pharmaceutical carrier such as an edible carbohydrate such as starch or mannitol.
• a flavor, preservative, dispersant and color may also be present.
• Capsules are made by making a powder mixture as described above and filling shaped gelatin shells with it.
• Lubricants such as e.g. finely divided silica, talc, magnesium stearate, calcium stearate or polyethylene glycol in solid form can be added to the powder mixture before the filling process.
• a disintegrant or solubilizer e.g. Agar, calcium carbonate or sodium carbonate can also be added to improve the availability of the medication after taking the capsule.
• suitable binding agents can also be incorporated into the mixture.
• suitable binders include starch, gelatin, natural sugars such as glucose or beta-lactose, sweeteners from corn, natural and synthetic gums such as acacia, tragacanth or sodium alginate, carboxymethyl cellulose, polyethylene glycol, waxes, etc.
• Lubricants include sodium oleate, sodium stearate, magnesium stearate, sodium benzoate, sodium acetate, sodium chloride, etc.
• the disintegrants include, but are not limited to, starch, methyl cellulose, agar, bentonite, xanthan gum, etc.
• the tablets are formulated, for example, by a powder mixture is produced, granulated or pressed dry, a lubricant and a disintegrant are added and the whole is pressed into tablets.
• a powder mixture is prepared by appropriately comminuting the compound with a diluent or a base as described above and optionally with a binder such as carboxymethyl cellulose, an alginate, gelatin or polyvinyl pyrrolidone, a solution retarder such as paraffin resorption tion accelerator, such as a quaternary salt and / or an absorbent, such as bentonite, kaolin or dicalcium phosphate, is mixed.
• the powder mixture can be granulated by using a binder such as carboxymethyl cellulose, an alginate, gelatin or polyvinyl pyrrolidone, a solution retarder such as paraffin resorption tion accelerator, such as a quaternary salt and / or an absorbent, such as bentonite,
• Binders e.g. Syrup, starch paste, Acadia mucus or solutions made of cellulose or polymer materials are wetted and pressed through a sieve.
• the powder mixture can be run through a tableting machine, with irregularly shaped ones
• Lumps are formed which are broken up into granules.
• the granules can be greased by adding stearic acid, a stearate salt, talc or mineral oil to prevent sticking to the tablet molds. The greased mixture is then compressed into tablets.
• the compounds according to the invention can also be combined with a free-flowing inert carrier and then pressed directly into tablets without carrying out the granulation or dry compression steps.
• a transparent or opaque protective layer consisting of a shellac seal, a layer of sugar or polymer material and a gloss layer of wax may be present. Dyes can be added to these coatings in order to be able to differentiate between different dosage units.
• Oral liquids such as solution, syrups and elixirs can be prepared in the form of dosage units so that a given quantity contains a given amount of the compound.
• Syrups can be made by dissolving the compound in an aqueous solution with a suitable taste, while elixirs are made using a non-toxic alcoholic vehicle.
• Suspensions can be formulated by dispersing the compound in a non-toxic vehicle.
• Solubilizers and emulsifiers such as, for example, ethoxylated isostearyl alcohols and polyoxyethylene sorbitol ethers, preservatives, flavor additives, such as, for example, peppermint oil or natural sweeteners or saccharin or other artificial sweeteners, can also be added.
• Dosage unit formulations for oral administration can optionally be enclosed in microcapsules. The formulation can also be prepared in such a way that the release is prolonged or retarded, for example by coating or embedding particulate material in poly
• the compounds of the formula I and salts, solvates and physiologically functional derivatives thereof can also be in the form of liposome delivery systems, such as Administer small unilamellar vesicles, large unilamellar vesicles and multilamellar vesicles.
• Liposomes can be made from various phospholipids, e.g. Cholesterol, stearyl laminate or phosphatidyl cholines are formed.
• the compounds of the formula I and the salts, solvates and physiologically functional derivatives thereof can also be supplied using monoclonal antibodies as individual carriers to which the compound molecules are coupled.
• the compounds can also be coupled with soluble polymers as targeted drug carriers.
• Such polymers can include polyvinylpyrrolidone, pyran copolymer, polyhydroxypropyl methacrylamide phenol, polyhydroxyethylaspartamide phenol or polyethylene oxide polylysine substituted with palmitoyl residues.
• the compounds can be linked to a class of biodegradable polymers suitable for achieving controlled release of a drug, e.g.
• Polylactic acid Polyepsilon-caprolactone, polyhydroxybutyric acid, polyorthoesters, polyacetals, polydihydroxy-pyrans, polycyanoacrylates and cross-linked or amphipatic block copolymers of hydrogels.
• compositions adapted for transdermal administration can be administered as independent patches for prolonged, close contact with the epidermis of the recipient.
• the active ingredient can be supplied from the patch by means of iontophoresis, as generally described in Pharmaceutical Research, 3 (6), 318 (1986).
• compositions adapted for topical administration can be used as ointments, creams, suspensions, lotions, powders, solutions,
• Pastes, gels, sprays, aerosols or oils can be formulated.
• the formulations are preferably applied as a topical ointment or cream.
• the active ingredient can be used either with a paraffinic or with a water-miscible cream base.
• the active ingredient can be formulated into a cream with an oil-in-water cream base or a water-in-oil base.
• compositions adapted for topical application to the eye include eye drops, the active ingredient being dissolved or suspended in a suitable carrier, in particular an aqueous solvent.
• compositions adapted for topical application in the mouth include lozenges, lozenges and mouthwashes.
• compositions adapted for rectal administration can be administered in the form of suppositories or enemas.
• compositions adapted for nasal administration in which the carrier substance is a solid, contain a coarse powder with a particle size, for example in the range of 20-500 micrometers, which is administered in the manner in which snuff is taken up, ie by rapid inhalation over the nasal passages from a container with the powder held close to the nose.
• Suitable formulations for administration as a nasal spray or nasal drops with a liquid as carrier include active ingredient solutions in water or oil.
• compositions adapted for administration by inhalation comprise finely particulate dusts or mists which can be generated by means of various types of pressurized metering dispensers with aerosols, nebulizers or insufflators.
• compositions adapted for vaginal administration can be administered as pessaries, tampons, creams, gels, pastes, foams or spray formulations.
• compositions adapted for parenteral administration include aqueous and non-aqueous sterile injection solutions containing antioxidants, buffers, bacteriostatics and solutes by which the formulation is rendered isotonic with the blood of the recipient to be treated; as well as aqueous and non-aqueous sterile suspensions, which can contain suspending agents and thickeners.
• the formulations can be in single dose or multiple dose containers, e.g. sealed ampoules and vials, presented and stored in the freeze-dried (lyophilized) state so that only the addition of the sterile carrier liquid, e.g. Water for injections is required immediately before use.
• Injection solutions and suspensions made according to the recipe can be made from sterile powders, granules and tablets.
• formulations may contain, in addition to the above-mentioned components, other means customary in the art with regard to the respective type of formulation; so can for example, formulations suitable for oral administration contain flavorings.
• a therapeutically effective amount of a compound of Formula I depends on a number of factors, including e.g. the age and weight of the animal, the exact condition of the disease that requires treatment, its severity, the nature of the formulation and the route of administration, and is ultimately determined by the treating doctor or veterinarian.
• an effective amount of a compound of the invention is generally in the range of 0.1 to 100 mg / kg of body weight of the recipient (mammal) per day and particularly typically in the range of 1 to 10 mg / kg of body weight per day.
• the actual amount per day would usually be between 70 and 700 mg, which amount as a single dose per day or more usually in a series of divided doses (such as two, three, four, five or six) per Day can be given so that the total daily dose is the same.
• An effective amount of a salt or solvate or a physiologically functional derivative thereof can be determined perse as a proportion of the effective amount of the compound of the invention. It can be assumed that similar dosages are suitable for the treatment.
• the compounds of formula I and their physiologically acceptable salts can be used in the control and prevention of thrombo-embolic diseases such as thrombosis, myocardial infarction, arteriosclerosis, inflammation, apoplexy, angina pectoris, restenosis after angioplasty, intermittent claudication, migraine, tumors, tumor diseases and / or tumor metastases can be used.
• thrombo-embolic diseases such as thrombosis, myocardial infarction, arteriosclerosis, inflammation, apoplexy, angina pectoris, restenosis after angioplasty, intermittent claudication, migraine, tumors, tumor diseases and / or tumor metastases can be used.
• the invention further relates to medicaments containing at least one compound of the formula I and / or their pharmaceutically usable Derivatives, solvates and stereoisomers, including their mixtures in all proportions, and at least one other active pharmaceutical ingredient.
• the invention also relates to a set (kit) consisting of separate packs of
• the set comprises suitable containers, such as boxes, indi- vidual ⁇ c bottles, bags or ampoules.
• the set can contain, for example, separate ampoules, in each of which an effective amount of a compound of the formula I and / or its pharmaceutically usable derivatives, solvates and stereoisomers, including their mixtures in all proportions, and an effective amount of a further active pharmaceutical ingredient are dissolved or dissolved lyophilized form is present.
• the invention furthermore relates to the use of compounds 5 of the formula I and / or their pharmaceutically usable derivatives, solvates and stereoisomers, including their mixtures in all ratios, for the manufacture of a medicament for the treatment of thromboses, myocardial infarction, arteriosclerosis, inflammation , Apoplexy, angina pectoris, restenosis after angioplasty, intermittent claudication, migraines, tumors, tumor diseases and / or tumor metastases, in combination with at least one other active pharmaceutical ingredient. 5
• Example A Injection glasses
• a solution of 100 g of an active ingredient of the formula I and 5 g of disodium hydrogenphosphate is adjusted to pH 6.5 in 3 l of double-distilled water with 2N hydrochloric acid, sterile filtered, filled into injection glasses, lyophilized under sterile conditions and sealed sterile. Each injection jar contains 5 mg of active ingredient.
• each suppository contains 20 mg of active ingredient.
• a solution of 1 g of an active ingredient is prepared of the formula I, 9.38 g of NaH 2 P0 4 ⁇ 2 H 2 0, 28.48 g Na 2 HP0 4 • 12 H 2 0 and 0.1 g of benzalkonium chloride in 940 ml of double distilled water. It is adjusted to pH 6.8, made up to 1 l and sterilized by irradiation. This solution can be used in the form of eye drops.
• Example D ointment
• 500 mg of an active ingredient of the formula I are mixed with 99.5 g of petroleum jelly under aseptic conditions.
• Example E tablets A mixture of 1 kg of active ingredient of the formula I, 4 kg of lactose, 1, 2 kg of potato starch, 0.2 kg of talc and 0.1 kg of magnesium stearate is compressed into tablets in a conventional manner such that each tablet contains 10 mg of active ingredient.
• Example F coated tablets
• Example E tablets are pressed, which are then coated in a conventional manner with a coating of sucrose, potato starch, talc, tragacanth and dye.
• Example G capsules
• each capsule contains 20 mg of the active ingredient.
• a solution of 1 kg of active ingredient of the formula I in 60 l of double-distilled water is sterile filtered, filled into ampoules, lyophilized under sterile conditions and sealed sterile. Each ampoule contains 10 mg of active ingredient.

Landscapes

• Organic Chemistry (AREA)
• Chemical & Material Sciences (AREA)
• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• General Health & Medical Sciences (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• General Chemical & Material Sciences (AREA)
• Pharmacology & Pharmacy (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Animal Behavior & Ethology (AREA)
• Medicinal Chemistry (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• Engineering & Computer Science (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Pain & Pain Management (AREA)
• Cardiology (AREA)
• Heart & Thoracic Surgery (AREA)
• Urology & Nephrology (AREA)
• Neurosurgery (AREA)
• Diabetes (AREA)
• Hematology (AREA)
• Oncology (AREA)
• Biomedical Technology (AREA)
• Neurology (AREA)
• Vascular Medicine (AREA)
• Rheumatology (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Hydrogenated Pyridines (AREA)
• Plural Heterocyclic Compounds (AREA)
• Nitrogen Condensed Heterocyclic Rings (AREA)
• Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
• Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Applications Claiming Priority (2)

Publications (1)

Family

ID=34638683

Family Applications (1)

Country Status (13)

Families Citing this family (9)

Family Cites Families (15)

• 2003
  • 2003-12-15 DE DE10358539A patent/DE10358539A1/de not_active Withdrawn
• 2004
  • 2004-11-19 WO PCT/EP2004/013202 patent/WO2005056528A1/de active Application Filing
  • 2004-11-19 CA CA002549548A patent/CA2549548A1/en not_active Abandoned
  • 2004-11-19 RU RU2006125380/04A patent/RU2006125380A/ru not_active Application Discontinuation
  • 2004-11-19 JP JP2006544246A patent/JP4990627B2/ja not_active Expired - Fee Related
  • 2004-11-19 BR BRPI0417153-5A patent/BRPI0417153A/pt not_active Application Discontinuation
  • 2004-11-19 AU AU2004296956A patent/AU2004296956B2/en not_active Ceased
  • 2004-11-19 US US10/582,850 patent/US7951804B2/en not_active Expired - Fee Related
  • 2004-11-19 KR KR1020067011538A patent/KR20060123305A/ko not_active Application Discontinuation
  • 2004-11-19 CN CNA2004800365005A patent/CN1890216A/zh active Pending
  • 2004-11-19 EP EP04820053A patent/EP1694643A1/de not_active Withdrawn
  • 2004-12-15 AR ARP040104655A patent/AR047850A1/es unknown
• 2006
  • 2006-07-14 ZA ZA200605839A patent/ZA200605839B/en unknown

Non-Patent Citations (1)

Also Published As

Similar Documents

Legal Events